Apellis PharmaceuticalsAPLS
13F holders, Q2 2026 (June 30)1holders −323
0new positions
318sold out
$41.03avg. 13F price*
At the end of Q2 2026, 1 institutions reported holding Apellis Pharmaceuticals Inc. (APLS) in their 13F filings, down 323 from Q1 2026. 0 opened new positions and 318 sold out. The largest holder was IFP Advisors, Inc ($10K).
- Company
- Apellis Pharmaceuticals Inc.
- CUSIP
- 03753U106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 318 | $5.6B |
All 13F filers, Q1 2026 → Q2 2026: 140,057,720 shares sold, net −140,057,720 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| IFP Advisors, Inc | 0.00% | Reduce -47.4% | 248 | $10K |
"% of holder's portfolio" is APLS's weight in each manager's 13F, not the share of Apellis Pharmaceuticals Inc. the manager owns.